Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Integrated transcriptomic and epigenomic analysis of ovarian cancer reveals epigenetically silenced GULP1.

Maldonado L, Brait M, Izumchenko E, Begum S, Chatterjee A, Sen T, Loyo M, Barbosa A, Poeta ML, Makarev E, Zhavoronkov A, Fazio VM, Angioli R, Rabitti C, Ongenaert M, Van Criekinge W, Noordhuis MG, de Graeff P, Wisman GBA, van der Zee AGJ, Hoque MO.

Cancer Lett. 2018 Jun 28;433:242-251. doi: 10.1016/j.canlet.2018.06.030. [Epub ahead of print]

PMID:
29964205
2.

Integrated time course omics analysis distinguishes immediate therapeutic response from acquired resistance.

Stein-O'Brien G, Kagohara LT, Li S, Thakar M, Ranaweera R, Ozawa H, Cheng H, Considine M, Schmitz S, Favorov AV, Danilova LV, Califano JA, Izumchenko E, Gaykalova DA, Chung CH, Fertig EJ.

Genome Med. 2018 May 23;10(1):37. doi: 10.1186/s13073-018-0545-2.

3.

Vive la radiorésistance!: converging research in radiobiology and biogerontology to enhance human radioresistance for deep space exploration and colonization.

Cortese F, Klokov D, Osipov A, Stefaniak J, Moskalev A, Schastnaya J, Cantor C, Aliper A, Mamoshina P, Ushakov I, Sapetsky A, Vanhaelen Q, Alchinova I, Karganov M, Kovalchuk O, Wilkins R, Shtemberg A, Moreels M, Baatout S, Izumchenko E, de Magalhães JP, Artemov AV, Costes SV, Beheshti A, Mao XW, Pecaut MJ, Kaminskiy D, Ozerov IV, Scheibye-Knudsen M, Zhavoronkov A.

Oncotarget. 2018 Feb 12;9(18):14692-14722. doi: 10.18632/oncotarget.24461. eCollection 2018 Mar 6. Review.

4.

Targeting focal adhesion kinase overcomes erlotinib resistance in smoke induced lung cancer by altering phosphorylation of epidermal growth factor receptor.

Solanki HS, Raja R, Zhavoronkov A, Ozerov IV, Artemov AV, Advani J, Radhakrishnan A, Babu N, Puttamallesh VN, Syed N, Nanjappa V, Subbannayya T, Sahasrabuddhe NA, Patil AH, Prasad TSK, Gaykalova D, Chang X, Sathyendran R, Mathur PP, Rangarajan A, Sidransky D, Pandey A, Izumchenko E, Gowda H, Chatterjee A.

Oncoscience. 2018 Feb 23;5(1-2):21-38. doi: 10.18632/oncoscience.395. eCollection 2018 Jan.

5.

Use of deep neural network ensembles to identify embryonic-fetal transition markers: repression of COX7A1 in embryonic and cancer cells.

West MD, Labat I, Sternberg H, Larocca D, Nasonkin I, Chapman KB, Singh R, Makarev E, Aliper A, Kazennov A, Alekseenko A, Shuvalov N, Cheskidova E, Alekseev A, Artemov A, Putin E, Mamoshina P, Pryanichnikov N, Larocca J, Copeland K, Izumchenko E, Korzinkin M, Zhavoronkov A.

Oncotarget. 2017 Dec 28;9(8):7796-7811. doi: 10.18632/oncotarget.23748. eCollection 2018 Jan 30.

6.

Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy.

Ravi R, Noonan KA, Pham V, Bedi R, Zhavoronkov A, Ozerov IV, Makarev E, V Artemov A, Wysocki PT, Mehra R, Nimmagadda S, Marchionni L, Sidransky D, Borrello IM, Izumchenko E, Bedi A.

Nat Commun. 2018 Feb 21;9(1):741. doi: 10.1038/s41467-017-02696-6.

7.

Converging blockchain and next-generation artificial intelligence technologies to decentralize and accelerate biomedical research and healthcare.

Mamoshina P, Ojomoko L, Yanovich Y, Ostrovski A, Botezatu A, Prikhodko P, Izumchenko E, Aliper A, Romantsov K, Zhebrak A, Ogu IO, Zhavoronkov A.

Oncotarget. 2017 Nov 9;9(5):5665-5690. doi: 10.18632/oncotarget.22345. eCollection 2018 Jan 19.

8.

NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis.

Peri S, Izumchenko E, Schubert AD, Slifker MJ, Ruth K, Serebriiskii IG, Guo T, Burtness BA, Mehra R, Ross EA, Sidransky D, Golemis EA.

Nat Commun. 2017 Nov 24;8(1):1772. doi: 10.1038/s41467-017-01877-7.

9.

Residual γH2AX foci induced by low dose x-ray radiation in bone marrow mesenchymal stem cells do not cause accelerated senescence in the progeny of irradiated cells.

Pustovalova M, Astrelina ТA, Grekhova A, Vorobyeva N, Tsvetkova A, Blokhina T, Nikitina V, Suchkova Y, Usupzhanova D, Brunchukov V, Kobzeva I, Karaseva Т, Ozerov IV, Samoylov A, Bushmanov A, Leonov S, Izumchenko E, Zhavoronkov A, Klokov D, Osipov AN.

Aging (Albany NY). 2017 Nov 21;9(11):2397-2410. doi: 10.18632/aging.101327.

10.

Integrated Analysis of Whole-Genome ChIP-Seq and RNA-Seq Data of Primary Head and Neck Tumor Samples Associates HPV Integration Sites with Open Chromatin Marks.

Kelley DZ, Flam EL, Izumchenko E, Danilova LV, Wulf HA, Guo T, Singman DA, Afsari B, Skaist AM, Considine M, Welch JA, Stavrovskaya E, Bishop JA, Westra WH, Khan Z, Koch WM, Sidransky D, Wheelan SJ, Califano JA, Favorov AV, Fertig EJ, Gaykalova DA.

Cancer Res. 2017 Dec 1;77(23):6538-6550. doi: 10.1158/0008-5472.CAN-17-0833. Epub 2017 Sep 25.

PMID:
28947419
11.

Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors.

Izumchenko E, Paz K, Ciznadija D, Sloma I, Katz A, Vasquez-Dunddel D, Ben-Zvi I, Stebbing J, McGuire W, Harris W, Maki R, Gaya A, Bedi A, Zacharoulis S, Ravi R, Wexler LH, Hoque MO, Rodriguez-Galindo C, Pass H, Peled N, Davies A, Morris R, Hidalgo M, Sidransky D.

Ann Oncol. 2017 Oct 1;28(10):2595-2605. doi: 10.1093/annonc/mdx416.

PMID:
28945830
12.

Mitochondria in chronic obstructive pulmonary disease and lung cancer: where are we now?

Nam HS, Izumchenko E, Dasgupta S, Hoque MO.

Biomark Med. 2017 May;11(6):475-489. doi: 10.2217/bmm-2016-0373. Epub 2017 Jun 9. Review.

13.

In silico analysis of pathways activation landscape in oral squamous cell carcinoma and oral leukoplakia.

Makarev E, Schubert AD, Kanherkar RR, London N, Teka M, Ozerov I, Lezhnina K, Bedi A, Ravi R, Mehra R, Hoque MO, Sloma I, Gaykalova DA, Csoka AB, Sidransky D, Zhavoronkov A, Izumchenko E.

Cell Death Discov. 2017 May 22;3:17022. doi: 10.1038/cddiscovery.2017.22. eCollection 2017.

14.

SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells.

Ozawa H, Ranaweera RS, Izumchenko E, Makarev E, Zhavoronkov A, Fertig EJ, Howard JD, Markovic A, Bedi A, Ravi R, Perez J, Le QT, Kong CS, Jordan RC, Wang H, Kang H, Quon H, Sidransky D, Chung CH.

Clin Cancer Res. 2017 Sep 1;23(17):5162-5175. doi: 10.1158/1078-0432.CCR-16-1686. Epub 2017 May 18.

PMID:
28522603
15.

Promoter methylation of MCAM, ERα and ERβ in serum of early stage prostate cancer patients.

Brait M, Banerjee M, Maldonado L, Ooki A, Loyo M, Guida E, Izumchenko E, Mangold L, Humphreys E, Rosenbaum E, Partin A, Sidransky D, Hoque MO.

Oncotarget. 2017 Feb 28;8(9):15431-15440. doi: 10.18632/oncotarget.14873.

16.

Comparative mutational landscape analysis of patient-derived tumour xenografts.

Brait M, Izumchenko E, Kagohara LT, Long S, Wysocki PT, Faherty B, Fertig EJ, Khor TO, Bruckheimer E, Baia G, Ciznadija D, Sloma I, Ben-Zvi I, Paz K, Sidransky D.

Br J Cancer. 2017 Feb 14;116(4):515-523. doi: 10.1038/bjc.2016.450. Epub 2017 Jan 24.

17.

In silico Pathway Activation Network Decomposition Analysis (iPANDA) as a method for biomarker development.

Ozerov IV, Lezhnina KV, Izumchenko E, Artemov AV, Medintsev S, Vanhaelen Q, Aliper A, Vijg J, Osipov AN, Labat I, West MD, Buzdin A, Cantor CR, Nikolsky Y, Borisov N, Irincheeva I, Khokhlovich E, Sidransky D, Camargo ML, Zhavoronkov A.

Nat Commun. 2016 Nov 16;7:13427. doi: 10.1038/ncomms13427.

18.

Chronic exposure to cigarette smoke leads to activation of p21 (RAC1)-activated kinase 6 (PAK6) in non-small cell lung cancer cells.

Raja R, Sahasrabuddhe NA, Radhakrishnan A, Syed N, Solanki HS, Puttamallesh VN, Balaji SA, Nanjappa V, Datta KK, Babu N, Renuse S, Patil AH, Izumchenko E, Prasad TS, Chang X, Rangarajan A, Sidransky D, Pandey A, Gowda H, Chatterjee A.

Oncotarget. 2016 Sep 20;7(38):61229-61245. doi: 10.18632/oncotarget.11310.

19.

Adenoid cystic carcinoma: emerging role of translocations and gene fusions.

Wysocki PT, Izumchenko E, Meir J, Ha PK, Sidransky D, Brait M.

Oncotarget. 2016 Oct 4;7(40):66239-66254. doi: 10.18632/oncotarget.11288. Review.

20.

Common pathway signature in lung and liver fibrosis.

Makarev E, Izumchenko E, Aihara F, Wysocki PT, Zhu Q, Buzdin A, Sidransky D, Zhavoronkov A, Atala A.

Cell Cycle. 2016 Jul 2;15(13):1667-73. doi: 10.1080/15384101.2016.1152435. Epub 2016 Jun 7.

21.

Pro-fibrotic pathway activation in trabecular meshwork and lamina cribrosa is the main driving force of glaucoma.

Zhavoronkov A, Izumchenko E, Kanherkar RR, Teka M, Cantor C, Manaye K, Sidransky D, West MD, Makarev E, Csoka AB.

Cell Cycle. 2016 Jun 17;15(12):1643-52. doi: 10.1080/15384101.2016.1170261.

22.

Patient-derived xenografts as tools in pharmaceutical development.

Izumchenko E, Meir J, Bedi A, Wysocki PT, Hoque MO, Sidransky D.

Clin Pharmacol Ther. 2016 Jun;99(6):612-21. doi: 10.1002/cpt.354. Epub 2016 Mar 9. Review.

PMID:
26874468
23.

Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA.

Izumchenko E, Chang X, Brait M, Fertig E, Kagohara LT, Bedi A, Marchionni L, Agrawal N, Ravi R, Jones S, Hoque MO, Westra WH, Sidransky D.

Nat Commun. 2015 Sep 16;6:8258. doi: 10.1038/ncomms9258.

24.

An integrated genome-wide approach to discover deregulated microRNAs in non-small cell lung cancer: Clinical significance of miR-23b-3p deregulation.

Begum S, Hayashi M, Ogawa T, Jabboure FJ, Brait M, Izumchenko E, Tabak S, Ahrendt SA, Westra WH, Koch W, Sidransky D, Hoque MO.

Sci Rep. 2015 Aug 28;5:13236. doi: 10.1038/srep13236.

25.

Understanding the MIG6-EGFR Signaling Axis in Lung Tumorigenesis.

Izumchenko E, Sidransky D.

Cancer Discov. 2015 May;5(5):472-4. doi: 10.1158/2159-8290.CD-15-0336.

26.

Cleaved NOTCH1 Expression Pattern in Head and Neck Squamous Cell Carcinoma Is Associated with NOTCH1 Mutation, HPV Status, and High-Risk Features.

Rettig EM, Chung CH, Bishop JA, Howard JD, Sharma R, Li RJ, Douville C, Karchin R, Izumchenko E, Sidransky D, Koch W, Califano J, Agrawal N, Fakhry C.

Cancer Prev Res (Phila). 2015 Apr;8(4):287-95. doi: 10.1158/1940-6207.CAPR-14-0366. Epub 2015 Jan 29.

27.

Involvement of epigenetics and EMT-related miRNA in arsenic-induced neoplastic transformation and their potential clinical use.

Michailidi C, Hayashi M, Datta S, Sen T, Zenner K, Oladeru O, Brait M, Izumchenko E, Baras A, VandenBussche C, Argos M, Bivalacqua TJ, Ahsan H, Hahn NM, Netto GJ, Sidransky D, Hoque MO.

Cancer Prev Res (Phila). 2015 Mar;8(3):208-21. doi: 10.1158/1940-6207.CAPR-14-0251. Epub 2015 Jan 13.

28.

Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients.

Zhu Q, Izumchenko E, Aliper AM, Makarev E, Paz K, Buzdin AA, Zhavoronkov AA, Sidransky D.

Hum Genome Var. 2015 Apr 2;2:15009. doi: 10.1038/hgv.2015.9. eCollection 2015.

29.

Notch1 mutations are drivers of oral tumorigenesis.

Izumchenko E, Sun K, Jones S, Brait M, Agrawal N, Koch W, McCord CL, Riley DR, Angiuoli SV, Velculescu VE, Jiang WW, Sidransky D.

Cancer Prev Res (Phila). 2015 Apr;8(4):277-286. doi: 10.1158/1940-6207.CAPR-14-0257. Epub 2014 Nov 18.

30.

The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors.

Izumchenko E, Chang X, Michailidi C, Kagohara L, Ravi R, Paz K, Brait M, Hoque MO, Ling S, Bedi A, Sidransky D.

Cancer Res. 2014 Jul 15;74(14):3995-4005. doi: 10.1158/0008-5472.CAN-14-0110. Epub 2014 May 15. Erratum in: Cancer Res. 2014 Sep 1;74(17):4950-1.

31.

The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors.

Chang X, Izumchenko E, Solis LM, Kim MS, Chatterjee A, Ling S, Monitto CL, Harari PM, Hidalgo M, Goodman SN, Wistuba II, Bedi A, Sidransky D.

PLoS One. 2013 Jul 31;8(7):e68966. doi: 10.1371/journal.pone.0068966. Print 2013.

32.

A requirement for Nedd9 in luminal progenitor cells prior to mammary tumorigenesis in MMTV-HER2/ErbB2 mice.

Little JL, Serzhanova V, Izumchenko E, Egleston BL, Parise E, Klein-Szanto AJ, Loudon G, Shubina M, Seo S, Kurokawa M, Ochs MF, Golemis EA.

Oncogene. 2014 Jan 23;33(4):411-20. doi: 10.1038/onc.2012.607. Epub 2013 Jan 14.

33.

Exonuclease 1 (Exo1) is required for activating response to S(N)1 DNA methylating agents.

Izumchenko E, Saydi J, Brown KD.

DNA Repair (Amst). 2012 Dec 1;11(12):951-64. doi: 10.1016/j.dnarep.2012.09.004. Epub 2012 Oct 11.

34.

WIF1 is a frequent target for epigenetic silencing in squamous cell carcinoma of the cervix.

Delmas AL, Riggs BM, Pardo CE, Dyer LM, Darst RP, Izumchenko EG, Monroe M, Hakam A, Kladde MP, Siegel EM, Brown KD.

Carcinogenesis. 2011 Nov;32(11):1625-33. doi: 10.1093/carcin/bgr193. Epub 2011 Aug 26.

35.

Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking NEDD9.

Singh MK, Izumchenko E, Klein-Szanto AJ, Egleston BL, Wolfson M, Golemis EA.

Cancer Res. 2010 Nov 1;70(21):8907-16. doi: 10.1158/0008-5472.CAN-10-0353. Epub 2010 Oct 12.

36.

NEDD9 promotes oncogenic signaling in mammary tumor development.

Izumchenko E, Singh MK, Plotnikova OV, Tikhmyanova N, Little JL, Serebriiskii IG, Seo S, Kurokawa M, Egleston BL, Klein-Szanto A, Pugacheva EN, Hardy RR, Wolfson M, Connolly DC, Golemis EA.

Cancer Res. 2009 Sep 15;69(18):7198-206. doi: 10.1158/0008-5472.CAN-09-0795. Epub 2009 Sep 8.

37.

A bacterial/yeast merged two-hybrid system: protocol for yeast screening with single or parallel baits.

Tikhmyanova NY, Izumchenko EA, Serebriiskii IG, Golemis EA.

Methods Mol Biol. 2007;408:257-90. doi: 10.1007/978-1-59745-547-3_15.

PMID:
18314588
38.

Cooperative antitumor effects of vitamin D3 derivatives and rosemary preparations in a mouse model of myeloid leukemia.

Sharabani H, Izumchenko E, Wang Q, Kreinin R, Steiner M, Barvish Z, Kafka M, Sharoni Y, Levy J, Uskokovic M, Studzinski GP, Danilenko M.

Int J Cancer. 2006 Jun 15;118(12):3012-21.

Supplemental Content

Loading ...
Support Center